enGene (NASDAQ:ENGN) Announces Earnings Results, Beats Expectations By $0.05 EPS

enGene (NASDAQ:ENGN) released its earnings results on Tuesday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05, Yahoo Finance reports.

enGene Trading Down 1.2 %

Shares of ENGN stock opened at $6.50 on Wednesday. The company has a quick ratio of 42.80, a current ratio of 42.80 and a debt-to-equity ratio of 0.09. enGene has a one year low of $4.94 and a one year high of $43.00. The company has a 50 day moving average price of $7.63 and a 200 day moving average price of $11.59.

Analyst Upgrades and Downgrades

Separately, Oppenheimer began coverage on enGene in a report on Wednesday, August 28th. They set an “outperform” rating and a $30.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.